Diagnostic Utility of N-Terminal Pro-B-Type Natriuretic Peptide in Identifying Atrial Fibrillation Post-Cryptogenic Stroke: A Systematic Review and Meta-Analysis

Background: Atrial fibrillation (AF) significantly contributes to acute ischemic stroke, with undetected AF being a common culprit in cryptogenic strokes. N-terminal pro-B-type natriuretic peptide (NT-proBNP), indicative of myocardial stress, has been proposed as a biomarker for AF detection, aiding in the selection of patients for extended cardiac monitoring. However, the diagnostic accuracy of NT-proBNP remains uncertain. Methods: We conducted a meta-analysis to evaluate the diagnostic accuracy of NT-proBNP in detecting AF among cryptogenic stroke patients. A comprehensive literature search was conducted across PubMed, Embase, and Cochrane databases to identify relevant studies. Studies reporting NT-proBNP levels in stroke patients and data on the proportion of patients with AF above a specified cut-off were included. Meta-analyses were performed using the midas command in STATA. Results: Seven studies encompassing 2171 patients were included in the analysis, of which five studies contained cohorts with cryptogenic strokes. Among patients with cryptogenic stroke, NT-proBNP demonstrated a diagnostic accuracy of 80% (Area Under the Receiver Operating Curve 0.80 [95% CI 0.76–0.83]), with a sensitivity of 81% (95% CI 0.68–0.89) and a specificity of 68% (95% CI 0.60–0.75). Conclusion: Our meta-analysis indicates that NT-proBNP exhibits a good-to-very-good diagnostic accuracy for detecting AF in patients with cryptogenic stroke. These findings suggest potential implications for utilizing NT-proBNP in guiding the selection of patients for prolonged cardiac monitoring, thereby aiding in the management of cryptogenic stroke cases.


Introduction
Atrial fibrillation (AF) stands as a prevalent cardiac arrhythmia globally, significantly contributing to both morbidity and mortality [1].It manifests as an irregularly irregular heart rhythm, categorized as paroxysmal, persistent, or permanent [2].The pathophysiology of AF is multifaceted, involving cardiac remodeling leading to structural and electrical changes [3].Additionally, AF correlates with various cardiovascular conditions, such as hypertension, valvular heart disease, and coronary heart disease, alongside risk factors like diabetes and smoking [3,4].
Among the primary concerns in AF patients lies the risk of acute ischemic stroke, attributed to vascular stasis potentially culminating in left atrial thrombus formation and subsequent embolization to the brain [5].Ischemic stroke is a major cause of disability and Pathophysiology 2024, 31 332 is a prominent contributor to the global burden of disease [6].As part of routine assessment, ischemic stroke patients undergo electrocardiography (ECG) to detect underlying AF [7].In cases where AF is identified, oral anticoagulant therapy is recommended to mitigate stroke recurrence [8].This recommendation holds particular relevance for patients with cryptogenic stroke, a subset of ischemic stroke where the stroke's cause remains unidentified despite investigation [9].In this subset, studies utilizing implantable cardiac monitors (ICMs) have revealed AF detection rates ranging from 26 to 36% after at least a year of monitoring [10,11].However, the logistical and economic challenges of long-term ICM monitoring pose limitations in its widespread application among cryptogenic stroke patients [12].Consequently, there is considerable interest in biomarkers capable of predicting AF post-stroke, facilitating patient stratification for prolonged cardiac monitoring [13].
One such potential biomarker is the N-terminal pro-B-type natriuretic peptide (NT-proBNP), released by atrial and ventricular cardiomyocytes in response to various stimuli such as myocardial wall stress, ischemia, and volume overload [14,15].Upon cleavage into the biologically active B-type natriuretic peptide (BNP), it induces vasodilation, increased fluid excretion, and inhibition of the renin-angiotensin-aldosterone system (RAAS) [14].While NT-proBNP and BNP biomarkers are currently employed to assess heart failure, particularly in emergency settings, to rule out cardiac cause of dyspnea [14], there is growing interest in their utility for AF diagnosis, especially in the context of stroke [16].
This meta-analysis aims to investigate the diagnostic accuracy of NT-proBNP in detecting AF following stroke, particularly in cryptogenic stroke patients.Diagnostic accuracy parameters such as sensitivity, specificity, and the Area Under the Receiver Operating Curve (AUROC) will be analyzed.Additionally, we will compare NT-proBNP accuracy in cohorts where the stroke's etiology is known, serving as a comparative measure.Our primary research questions are the following: What is the diagnostic accuracy of NT-proBNP in detecting AF in patients with cryptogenic stroke?(As a secondary aim, we will investigate NT-proBNP accuracy in cohorts where the stroke's etiology is established, thus formulating our secondary research question).

2.
What is the diagnostic accuracy of NT-proBNP in detecting AF in patients with stroke of known etiology?

Literature Search: Identification and Selection of Studies
We selected studies from the databases of PubMed, Embase, and Cochrane.We obtained additional studies from Google Scholar and conducted hand searching within the references of other studies.The PRISMA flowchart illustrates the process of study identification and screening, providing the number of studies at each stage and the reasons for study exclusion (Figure 1).Details of the keywords and filters used can be found in Supplemental Information (Search Strategy).We conducted this study following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and adhered to the Meta-analysis of Observational Studies in Epidemiology (MOOSE) checklist (Supplemental Tables S1 and S2), as well as the Standards for Reporting Diagnostic Accuracy Studies (STARD) 2015 guidelines (Supplementary Table S3).This study was registered in Open Science, registration number "pn27u" (https://osf.io/pn27u/(accessed on 24 March 2024).

Inclusion and Exclusion Criteria
The study's inclusion criteria encompassed (1) patients diagnosed with acute ischemic stroke; (2) patients aged 18 years and above; (3) a defined cut-off value for high NT-proBNP levels; (4) availability of data on the number of AF and non-AF patients with NT-proBNP levels above and below the cut-off; and (5) studies with robust methodological design, requiring a minimum sample size of 20 patients.Studies meeting these criteria were included, while those failing to meet these conditions were excluded.Criteria for exclusion included (1) animal studies; (2) inaccessible studies where the complete report

Inclusion and Exclusion Criteria
The study's inclusion criteria encompassed (1) patients diagnosed with acute ischemic stroke; (2) patients aged 18 years and above; (3) a defined cut-off value for high NT-proBNP levels; (4) availability of data on the number of AF and non-AF patients with NT-proBNP levels above and below the cut-off; and (5) studies with robust methodological design, requiring a minimum sample size of 20 patients.Studies meeting these criteria were included, while those failing to meet these conditions were excluded.Criteria for exclusion included (1) animal studies; (2) inaccessible studies where the complete report could not be retrieved; (3) studies published in languages other than English; and (4) studies sourced from the same database as another included study in the meta-analysis.

Data Extraction
Data extraction involved screening the titles and abstracts of identified studies using EndNote 20.6 (Clarivate, Philadelphia, PA, USA).Studies that did not align with the specified inclusion and exclusion criteria were excluded at this stage.From studies passing this initial screening, full texts were retrieved when feasible, and eligibility was further assessed.This screening process was conducted independently by two authors, with any disagreements resolved through discussion until consensus was achieved.
From the studies included in the meta-analysis, data were extracted and organized into a comprehensive spreadsheet.This spreadsheet documented the following information: (1) study characteristics (author, title, year, country, study type); (2) stroke cohort (cryptogenic stroke or stroke of known origin); (3) basic patient characteristics (number of means, mean age, proportion of male sex); (4) prevalence of comorbidities (hypertension, diabetes, dyslipidemia, smoking); (5) NT-proBNP cut-off level; and (6) number of AF and non-AF patients with NT-proBNP levels above and below the cut-off, necessary for sensitivity and specificity calculations.In instances where age was reported using the median and interquartile range (with a clearly stated value for the upper and lower quartile), the mean age and standard deviation were estimated using the method described by Wan et al. [23].

Methodological Quality Assessment of Included Studies
To assess the methodological quality of the studies in the meta-analysis, we evaluated each study using the criteria outlined in the modified Jadad scale [24].This included considering factors such as randomization and blinding, as well as clear descriptions of the inclusion and exclusion criteria and the statistical analysis method.The complete criteria and evaluation for each study are detailed in Supplementary Table S4.Additionally, we investigated the potential for funding bias by examining the presence of industry funding and conflicts of interest among authors.The evaluation of funding bias is also provided in Supplementary Table S4.

Statistical Analyses
We utilized STATA (Version 13.0, StataCorp, College Station, TX, USA) for statistical analyses.We analyzed the diagnostic accuracy of NT-proBNP in identifying AF following stroke through meta-analyses.These meta-analyses were conducted when at least four studies were available for a given analysis.We employed the midas package in STATA for these analyses.The required data for this command included (1) true positives or "tp" (number of patients with NT-proBNP levels above the cut-off diagnosed with AF); (2) false positives for "fp" (number of patients with NT-proBNP levels above the cut-off but without AF); (3) false negatives or "fn" (number of patients with NT-proBNP levels below the cut-off but with AF); and (4) true negatives or "tn" (number of patients with NT-proBNP levels below the cut-off without AF).
With these data, the midas package in STATA calculated the sensitivity and specificity of each study.It also combined these data to provide pooled sensitivity and specificity and constructed forest plots.We generated summary receiver operating characteristic (SROC) curves and assessed the AUROC as an overall measure of diagnostic accuracy.A well-established definition was used to describe the relationship between AUROC, and diagnostic accuracy, whereby an AUROC of 0.9-1 represents excellent diagnostic accuracy, an AUROC of 0.8-0.9 is very good diagnostic accuracy, an AUROC of 0.7-0.8 is good, an AUROC of 0.6-0.7 is sufficient, an AUROC 0.5-0.6 is bad diagnostic accuracy, and an AUROC less than 0.5 suggests that a diagnostic accuracy test is not useful [25].The STATA output additionally provided information regarding positive and negative likelihood ratios alongside graphs representing the likelihood matrix.For all analyses in this study, we considered p-values less than 0.05 as statistically significant.Heterogeneity was assessed using the I 2 statistic, where values of 0-40%, 30-60%, 50-90%, and 75-100% represented low, moderate, substantial, and considerable heterogeneity, respectively [26].

Results of the Search
The search across PubMed, Embase, and Cochrane databases yielded 431 studies, as outlined in the PRISMA flowchart (Figure 1).Additionally, 29 studies were sourced from Google Scholar, and 9 were identified through manual citation searching within previous studies.Following the removal of duplicates, titles, and abstracts, 332 studies were screened using EndNote.Among these, 23 were found to approximately align with our study criteria, and full-text reports of 21 studies were obtained.These 21 studies underwent rigorous screening to assess their alignment with our study's inclusion and exclusion criteria.Fourteen studies were excluded, with reasons detailed in the PRISMA flowchart (Figure 1).Consequently, seven studies met the criteria for inclusion in our systematic review and meta-analysis.

Description of the Included Studies
This meta-analysis comprised seven studies [13,[17][18][19][20][21][22], encompassing a total of 2171 patients.Of these, five studies [13,17,[19][20][21] focused on assessing the diagnostic accuracy of NT-proBNP in detecting AF among patients with cryptogenic stroke, while four studies [13,18,19,22] evaluated its diagnostic accuracy in patients with stroke of known origin.Table 1 presents the baseline characteristics of the studies within the meta-analysis, encompassing study type, country, sex distribution, mean age, and the AF detection method employed in each study.Table 2 provides additional information on the prevalence of various comorbidities within each cohort.A summary of the sensitivities and specificities observed in each individual study cohort is provided in Table 3.Additionally, Table 4 provides a detailed overview of the outcomes derived from the diagnostic accuracy metaanalyses conducted for cohorts of patients with cryptogenic stroke and those with stroke of known origin.As stated above, with additional serial 24-h Holter monitoring conducted during follow-ups between 3 and 6 months.
Diagnosis of cryptogenic stroke was made using the TOAST criteria [27].If a patient had a history of AF and no other findings were disclosed, then they were classified as cardioembolic rather than cryptogenic.
ECG in all patients.In those with cardioembolic stroke, ECG, and 24-h Holter after admission.This was repeated within seven days in patients with STAF ≥5, where AF was still not found [28].
Additionally, either a TEE or TOE was conducted on each patient.Abbreviations: NT-proBNP = N-terminal pro-B-type natriuretic peptide, CI = confidence interval, AUROC = area under receiver operating characteristic curve, PLR = positive likelihood ratio, NLR = negative likelihood ratio, AIC = Akaike information criteria, BIC = Bayesian information criteria, ICC_SEN = interstudy variation in sensitivity, MED_SEN = interstudy variation in sensitivity, ICC_SPE = interstudy variation in specificity, MED_SPE = interstudy variation in specificity, I 2 = percentage of variation among studies due to heterogeneity.

Discussion
Pooling the current data, our study revealed that NT proBNP had a good-to-verygood diagnostic accuracy for detecting AF following cryptogenic stroke.This may have promising applications in stratifying patients for cardiac monitoring.The sensitivity and specificity of NT-proBNP for AF detection were comparatively higher in patients with stroke of known etiology, possibly due to variations in AF subtypes among different patient groups.
Our investigation builds upon the findings of a previous meta-analysis by Zhang et al. [16], which reported NT-proBNP's sensitivity at 91% and specificity at 77% in detecting covert AF following stroke.However, our meta-analysis on cryptogenic stroke yielded lower sensitivity and specificity values, likely attributable to differences in the composition of included studies.Notably, our study incorporated three additional datasets concerning cryptogenic stroke [13,17,20], and one dataset from Fonseca et al. [19], previously analyzed within Zhang et al. [16]), was reassigned to the section focusing on stroke of known etiology.Additionally, we excluded the study by Sanak et al. [29] due to its restriction to patients under 50.Although investigating biomarker accuracy in younger patients holds importance, our inclusion criteria aimed to encompass all adults aged 18 and above without imposing additional age limits.
Our study contributes to the expanding body of evidence suggesting NT-proBNP holds potential as a biomarker for AF following cryptogenic stroke [16,19,30].Offering a straightforward test, NT-proBNP empowers clinicians to evaluate each cryptogenic stroke patient's likelihood of having underlying AF more precisely [21].This capability proves invaluable in resource allocation, as those cryptogenic stroke patients deemed at a high risk of AF stand as prime candidates for extended cardiac monitoring, such as implantable loop recorders [21,31].Recent findings from a randomized controlled trial further underscore the advantages of NT-proBNP, revealing that implantable loop-recorder screening

Discussion
Pooling the current data, our study revealed that NT proBNP had a good-to-verygood diagnostic accuracy for detecting AF following cryptogenic stroke.This may have promising applications in stratifying patients for cardiac monitoring.The sensitivity and specificity of NT-proBNP for AF detection were comparatively higher in patients with stroke of known etiology, possibly due to variations in AF subtypes among different patient groups.
Our investigation builds upon the findings of a previous meta-analysis by Zhang et al.
[16], which reported NT-proBNP's sensitivity at 91% and specificity at 77% in detecting covert AF following stroke.However, our meta-analysis on cryptogenic stroke yielded lower sensitivity and specificity values, likely attributable to differences in the composition of included studies.Notably, our study incorporated three additional datasets concerning cryptogenic stroke [13,17,20], and one dataset from Fonseca et al. [19], previously analyzed within Zhang et al. [16]), was reassigned to the section focusing on stroke of known etiology.Additionally, we excluded the study by Sanak et al. [29] due to its restriction to patients under 50.Although investigating biomarker accuracy in younger patients holds importance, our inclusion criteria aimed to encompass all adults aged 18 and above without imposing additional age limits.
Our study contributes to the expanding body of evidence suggesting NT-proBNP holds potential as a biomarker for AF following cryptogenic stroke [16,19,30].Offering a straightforward test, NT-proBNP empowers clinicians to evaluate each cryptogenic stroke patient's likelihood of having underlying AF more precisely [21].This capability proves invaluable in resource allocation, as those cryptogenic stroke patients deemed at a high risk of AF stand as prime candidates for extended cardiac monitoring, such as implantable loop recorders [21,31].Recent findings from a randomized controlled trial further underscore the advantages of NT-proBNP, revealing that implantable loop-recorder screening correlates with a greater reduction in stroke risk among patients exhibiting higher NT-proBNP levels [31].Ensuring thorough diagnostic investigation is imperative, given that detecting AF typically prompts a shift in secondary stroke-prevention strategy from antiplatelets to oral anticoagulants [19], known for their favorable efficacy and safety profile in AF patients [32].A limitation of our meta-analysis is that there were inconsistencies in the timing of AF diagnosis post-enrolment in each study, and the duration of cardiac monitoring varied.The most common approach to AF detection was an ECG on admission and 24-h Holter monitoring; however, prolonged ECG monitoring outside the hospital was not always conducted.As a result, AF may have been underdiagnosed in some cases.Specific information on the AF detection strategies employed in each study is described in Table 1.In the era of reperfusion therapy, AF is an important clinical consideration as it mediates outcomes in acute ischemic stroke patients treated with intravenous thrombolysis [33].This adds weight to the importance of NT-proBNP assessment, indicating that it may even be crucial in acutely prognosticating patients treated with reperfusion therapy.
Our study observed a higher diagnostic accuracy of NT-proBNP in patients with known etiology strokes than in those with cryptogenic strokes.This discrepancy likely stems from differences in AF subtypes between the two groups.Paroxysmal AF, known for its elusive detection compared to persistent or permanent AF [34], is presumed to be more prevalent in the cryptogenic stroke cohort than in patients with known etiology strokes [35].Consequently, it is plausible that a larger proportion of patients in the cryptogenic stroke cohorts harbor undiagnosed paroxysmal AF.These patients may manifest as false positives in our analysis, potentially accounting for the comparatively lower specificity of 68%.To provide a more accurate assessment of NT-proBNP's efficacy in cryptogenic stroke, future studies should extend the duration of cardiac monitoring to capture paroxysmal AF episodes better [36].Moreover, a limitation lies in the variation in AF subtypes among different cohorts and inconsistent reporting of the number of patients with each subtype.Furthermore, the definition of cryptogenic stroke in each cohort (as described in Table 1) was not entirely consistent with the studies.Addressing these factors would enhance the precision and generalizability of our findings.
The elevation of NT-proBNP in AF patients primarily stems from increased stretching and stress on the myocardial wall [14].Particularly, NT-proBNP levels are notably raised in AF patients with left atrial enlargement [37].However, even in AF patients without left atrial enlargement, NT-proBNP levels remain higher than in non-AF patients, suggesting that the asynchronous myocardial stretches inherent in AF also contribute to NT-proBNP release [37].Furthermore, NT-proBNP levels tend to decrease as the heart returns to sinus rhythm, resulting in lower levels in patients with paroxysmal AF compared to those with persistent or permanent AF [38].This dynamic pattern reduces the effectiveness of NT-proBNP in cryptogenic stroke, where its primary potential lies in the risk stratification of patients with paroxysmal AF.A clinically significant entity is atrial cardiopathy, characterized by an elevated NT-proBNP and an increased stroke risk, often in the absence of AF [30,39].In our study, these patients may have appeared as false positives, leading to an underestimation of specificity.Given that atrial cardiopathy frequently precedes AF, there remains uncertainty regarding the potential benefits of anticoagulation in these patients [30,39].
To improve the accuracy of NT-proBNP in clinical practice, researchers have explored several other biomarkers and clinical factors that can complement its diagnostic potential [30].For instance, Kneihsl et al. [20] demonstrated that while NT-proBNP alone had a sensitivity of 58.3% in detecting AF following cryptogenic stroke, this sensitivity increased to 92% when integrating a risk score combining NT-proBNP with age and various indicators from brain imaging and echocardiography.Advanced machine learning algorithms may also aid in the prognostication of patients with suspected AF [40].In addition to NT-proBNP, other biomarkers have been traditionally used; however, their efficacy in de-tecting AF has been variable and comparatively suboptimal for clinical use [41].A detailed overview of these biomarkers is provided in Table 5. Troponin elevations are a predictor of AF in cryptogenic stroke [43,44]; however, there is limited data on their sensitivity in this context.
Whilst troponins are associated with AF in cryptogenic stroke patients [43,44], there are limited data on their exact specificity.

D-dimer
A product of the degradation of fibrin, typically used in venous thromboembolism, may also be increased in patients with AF [45].
Limited data with various indications.
Limited data with various indications.

CRP
CRP is a biomarker that reflects systemic inflammation, which may reflect underlying AF, though it is generally non-specific [46].
Whilst cumulative exposure to CRP has been linked to AF, baseline CRP was shown not to be significantly associated with AF [46].Moreover, there is a lack of data regarding the accuracy of CRP for diagnosing AF in cryptogenic stroke patients.
Limited data with various indications.
Limited data with various indications.

Galectin-3
Galectin-3 is a biomarker associated with myocardial fibrosis, which can occur due to structural remodeling in AF [47].
A prospective study reported that a galactin-  Oxidative stress is a factor involved in the pathogenesis of AF, and there are numerous biomarkers of oxidative stress that may be elevated in AF patients [49].
Whilst MDA activity is associated with AF [50], there are limited data on the diagnostic accuracy of oxidative stress biomarkers in the setting of cryptogenic stroke.
Limited data with various indications.
Limited data with various indications.Alongside blood-based biomarkers, growing evidence supports the role of clot morphology in determining the etiology of cryptogenic stroke [51][52][53].Furthermore, standard cardiovascular laboratory parameters such as triglycerides and total cholesterol have also been shown to enhance the ability of NT-proBNP to distinguish between stroke of cardioembolic or large-artery atherosclerotic origin [54].A recent prospective study also identified several biomarkers associated with AF in cryptogenic stroke patients [41].Notably, NT-proBNP emerged as the robust predictor of AF at baseline and after 12-month follow-up [41].Despite numerous proposals for tools or scores to assess the likelihood of AF post-stroke [17,20,55,56], a standardized system remains elusive.Similar to the CHA 2 DS 2 -VASc score's role in guiding AF treatment [57], future research efforts could aim at developing a tool for AF detection.Our findings corroborate existing literature [20,39,41], suggesting that NT-proBNP could play a significant role in such a tool.

Limitations
Our study had several limitations.Primarily, we identified only five studies meeting the inclusion criteria for our analysis on cryptogenic stroke [13,17,[19][20][21] and four studies for the analysis on stroke of known etiology [13,18,19,22].The main reason for this limitation was the necessity to exclude studies where we could not precisely determine the number of AF and non-AF patients with NT-proBNP levels above and below the cut-offs.Some of these studies reported rounded-off values for sensitivity and specificity [41,58], which were not compatible with the raw numbers required as inputs for the midas command in STATA.Additionally, one study utilized the lower and upper NT-proBNP quartiles as cut-offs to create high-sensitivity and high-specificity models instead of opting for a cut-off that balanced both [44].
The variations in NT-proBNP cut-offs emerged as a major limitation of this study.There were considerable variations in NT-proBNP cut-offs in our study, ranging from 250 pg/mL to 505 pg/mL (Table 3).Theoretically, a lower cut-off (such as 250 pg/mL) would yield higher sensitivity for AF diagnosis but lower specificity, and vice versa for a higher cut-off (such as 505 pg/mL).Unfortunately, there were insufficient studies at these data points for us to conduct subgroup analyses, and determining the ideal cut-off remains an area for future primary research.It is also possible that there is no single "ideal" cut-off, as clinicians may benefit from considering patient demographics and resource availability to decide if a higher-specificity or higher-sensitivity approach is more suitable for their circumstances.Nevertheless, our data suggest that any NT-proBNP value within the range of 250 to 505 pg/mL provides reasonable sensitivity and specificity for AF detection post-stroke.
While we initially planned to conduct a meta-analysis to evaluate differences in the mean NT-proBNP levels between AF and non-AF patients in these studies, the necessary data for this analysis were often unavailable and occasionally reported as the median and interquartile range without providing the first and third quartiles.Unfortunately, the software required mean and standard deviation values.Another limitation is that our study only utilized a single measurement of NT-proBNP rather than tracking changes over time.This is crucial, as the stroke itself may influence NT-proBNP levels due to the release of pro-inflammatory cytokines [30].Lastly, our analysis focused on diagnostic accuracy.Therefore, while we suggested that NT-proBNP may be useful in stratifying patients for prolonged cardiac monitoring, further research is necessary to investigate which cardiac monitoring forms are most suitable for these patients, considering patient outcomes and resource allocation.

Conclusions
In conclusion, our study emphasizes the rapid increase in NT-proBNP concentration following the onset of atrial fibrillation, reinforcing the utility of this biomarker in early detection and diagnosis.Our meta-analysis found that NT-proBNP demonstrates good-tovery-good diagnostic accuracy in detecting AF following cryptogenic stroke, with excellent accuracy observed in patients with stroke of known etiology.This meta-analysis updates and consolidates the data to assess the diagnostic accuracy of NT-proBNP in detecting AF in the context of stroke.An integrated approach combining NT-proBNP measurements with ECG telemetry, clinical factors, and imaging tests like transthoracic and transesophageal echocardiography is critical in identifying the cause of stroke and enhancing diagnostic accuracy.Although consensus on a standardized risk tool is still pending, from a clinical perspective, NT-proBNP holds promise in identifying cryptogenic stroke patients who would benefit from extended cardiac monitoring.Further primary research is warranted to determine the optimal cut-off for NT-proBNP and to identify the most effective form of cardiac monitoring for these patients.

Figure 1 .
Figure 1.PRISMA flowchart depicting the process of study identification, screening, and inclusion.Abbreviations: N = number of studies, n = total number of patients, AF = atrial fibrillation, NT-proBNP = N-terminal pro-B-type natriuretic peptide.

Figure 1 .
Figure 1.PRISMA flowchart depicting the process of study identification, screening, and inclusion.Abbreviations: N = number of studies, n = total number of patients, AF = atrial fibrillation, NT-proBNP = N-terminal pro-B-type natriuretic peptide.

-
Abbreviations: AF = atrial fibrillation, n = number of patients, SD = standard deviation, ECG = electrocardiogram, ILR = implantable loop recorder, STAF = score for the targeting of atrial fibrillation, TTE = transthoracic echocardiogram, TOE = transesophageal echocardiogram, TOAST = Trial of Org 10172 in Acute Stroke Treatment.a This was a retrospective analysis of a prospectively collected dataset.b This study was used in the stroke of known etiology meta-analysis since it classified the stroke etiology as cardioembolic or non-cardioembolic.c This study reported the ages using the median (interquartile range) for these cohorts.d This study matched AF and non-AF patients.

Table 1 .
Baseline Characteristics of Studies Included in the Meta-analysis.

Table 2 .
Prevalence Rates of Comorbidities among Studies Included in the Meta-analysis.
Abbreviation: n = number of patients.

Table 3 .
Sensitivity and Specificity of NT-proBNP in Detecting AF within Each Individual Study Cohort.

Table 4 .
Meta-analysis Summary of NT-proBNP Diagnostic Accuracy in AF Detection Post-stroke.

Table 5 .
Various Biomarkers and their Diagnostic Accuracy, Sensitivity, and Specificity in Identifying Atrial Fibrillation Following Cryptogenic Stroke.